Canaccord initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $110 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Nike downgraded, IBM initiated: Wall Street’s top analyst calls
- Ionis Pharmaceuticals resumed with an Outperform at Raymond James
- Ionis Pharmaceuticals price target raised to $111 from $100 at BofA
- Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors
- Ionis Pharmaceuticals management to meet with Oppenheimer